Wolfe Research Upgrades AbbVie to Outperform, Announces $300 Price Target

Benzinga Newsdesk www.benzinga.com Positive 93.4%

Neg 0% Neu 0% Pos 93.4%

Wolfe Research analyst Alexandria Hammond upgrades AbbVie (NYSE:ABBV) from Peer Perform to Outperform and announces $300 price target.